Business
Dr. David Maberley MD, FRCS(C), MSc joins Medical Advisor Board of Canadian Bio Med Systems Inc.
Dr. David Maberley MD, FRCS(C), MSc joins Medical Advisor Board of Canadian Bio Med Systems Inc..
About this update from Icbs Ltd
[{"type":"text","content":"NEW YORK, MONTREAL, SAN DIEGO, May 24, 2010 Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT),) , and Ocular Therapeutics Inc., of San Diego California, announced today that Dr David Maberley, of the Department of Ophthalmology The University of British Columbia has joined the Medical Advisory Board of CBMS. David Maberley MD, FRCS(C), MSc is the director of the Vancouver Native Health Society’s Eye Clinic. Dr. Maberley sits on the Board of Directors of the .Canadian Ophthalmology Society and is also on the Diabetic Retinopathy Guidelines Committee . He has written Surgical and medical management of proliferative diabetic retinopathy; Cost-effectiveness of screening and treatment; Management of PDR and CSME; Management of ischemic maculopathy.Head of Vitreoretinal section of Canadian Ophthalmology Society. Dr. Maberley is ophthalmic director of the BC On-reserve Telemedicine ProjectConsultant for VIHA Teleophthalmology Program and is editor (retina) for Canadian Journal of Ophthalmology.Commenting on the latest member of the Medical Advisory Board, Dr. George Tsoukas, Medical Director (CBMS), says \"Dr. Maberley is a major asset to help direct our efforts in solving the problems of Age-related Macular degeneration.. His experience will add greatly to our ability to move forward.\"Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for persons aged 80. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.The drug under development by Canadian Bio Med Systems , has a very different mode of action than the current therapeutic products. It can be used alone or in conjunction with these currently available products.The product under development by CBMS, LD22-4 has the advantage of being a very small molecule meaning that fewer treatments will be needed compared to current therapies, This will help reduce the pain and frequency of injection to the patient and potentially the cost of the treatment.Canadian Bio Med is developing the new product in Montreal in conjunction with its partner, Ocular Therapeutics Inc. of San Diego, California. The drug is ...